Screening and care for fear that breast or lung cancer will come back or get worse at Institut Curie
Official title: Fear of Cancer Recurrence: Prevalence, Lived Experience and Satisfaction of Supportive Care Needs in the Hospital Care Pathway. A Mixed Method Study.
Run by Institut Curie · NCT07357311 · Data updated 2026-11-12
This project will test brief screening methods to find people at Institut Curie with severe fear that their breast or lung cancer will come back or progress so they can get appropriate help.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Institut Curie Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | September 8, 2025 |
| Main results expected | January 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | January 23, 2026 |
| Trial ID | NCT07357311 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a diagnosis of breast or lung cancer — including localized, locoregional, or metastatic disease — who are at least three months post-treatment or three months into first-line metastatic therapy and can read French are the intended participants.
✕Probably not a fit
Patients who cannot read French, cannot complete questionnaires, are under guardianship or detention, or who are enrolled in conflicting patient-reported outcome studies are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will measure how common severe fear of cancer recurrence or progression (FCR) is among French-speaking breast and lung cancer patients treated at Institut Curie. Eligible adults will complete the Fear of Recurrence Inventory (FCRI) and related questionnaires at least three months after finishing treatment or three months into a first-line metastatic therapy. The team will seek threshold scores for the FCRI 9-item severity scale by cancer type and evaluate whether a single FCRI item can reliably flag high FCR for routine or digital screening. The goal is to culturally validate shorter screening tools in French and identify patients who need a targeted psychotherapeutic response.
Why it matters
Potential benefit: If successful, this work could enable simpler, earlier detection of severe FCR so more patients receive timely psychological support and improved quality of life.
How similar studies have gone: The FCRI is widely validated and shorter screening items have been used in other settings, but established cut-offs for French-speaking breast and lung cancer populations and systematic study in metastatic patients remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 or over * Clinical or pathological diagnosis of primary or recurrence of a localized/loco-regional or metastatic breast cancer, or a stage 1 or 2, or stage 3 or 4 lung cancer; or a breast or lung cancer metastatic progression * Three months after completing treatment or three months after the start of a first treatment line for metastatic progression * Able to comply with the scheduled assessment and interviews * Able to read and understand the questionnaires' language (i.e. French) Exclusion Criteria: * Participating in another patient-reported outcome study interfering with the present study * Any social, medical or psychological condition hindering questionnaire completion * Being deprived of personal liberty or under guardianship
Where it's running
-
Institut Curie
Paris, France Recruiting
Study contacts
- Study coordinator: Anne Bredart, Ph.D
- Email: anne.bredart@curie.fr
- Phone: +33 1 44 32 43 50
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Heart-friendly medicines to protect chest-area cancer patients from radiation damage
This Phase 2 trial tests whether taking atorvastatin and lisinopril can reduce heart damage in adults with chest-area cancers who receive radiation therapy.
-
Precision navigation to boost cancer screening participation in high-risk communities
This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.
-
Side Effects and Resource Navigation Program for Cancer Patients
This program tests whether a navigation service helps adults with kidney, bladder, breast, or lung cancer manage immunotherapy better than usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.